OncoMatch/Neuroendocrine Tumor (NET)/SSTR (somatostatin receptor)
Neuroendocrine Tumor (NET)SSTR (somatostatin receptor) Clinical Trials
Somatostatin receptor (SSTR) positivity — assessed by 68Ga-DOTATATE/DOTATOC PET or In-111 octreoscan — defines eligibility for peptide receptor radionuclide therapy (PRRT) with lutetium-177 DOTATATE (Lutathera), which is FDA-approved for SSTR-positive gastroenteropancreatic NETs. SSTR expression also guides somatostatin analogue (octreotide, lanreotide) use. Trials investigate 177Lu-DOTATATE in SSTR-positive lung and other NETs, actinium-225 DOTATATE, and combinations with targeted agents.
Top recruiting SSTR (somatostatin receptor) Neuroendocrine Tumor (NET) trials
Ranked by phase and US site count. See all 4 trials matched to your profile →
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Crinetics Pharmaceuticals Inc.
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
Perspective Therapeutics
177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry
University of Iowa
"Receptor Radionuclide Therapy With 177Lu-DOTATOC
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Browse other molecular targets with active Neuroendocrine Tumor (NET) trials.